Dylan is an associate in our New York office focusing on M&A and corporate matters. During law school, Dylan served as an intern at the Center for Ethics and Rule of Law in Philadelphia. He conducted research in conjunction with the legal ethics group CREW in Washington D.C. contributing to a comprehensive report critically analyzing U.S. Department of Justice practices under Attorney General William Barr.
Prior to joining Freshfields, Dylan worked as an upstream process development scientist at a contract development and manufacturing organization specializing in microbial fermentation.
back to tab navigation
- AbbVie on a strategic collaboration and option-to-license agreement with Gilgamesh Pharmaceuticals to develop next-generation therapies for psychiatric disorders.
- Merz Therapeutics on its $185 million acquisition of Acorda Therapeutics, Inc.
- AstraZeneca on its acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, worth up to $2.4 billion.
- AstraZeneca on its acquisition of Gracell Biotechnologies.
- Johnson & Johnson on its $13.1 billion pending acquisition of Shockwave Medical, Inc.
- Basilea Pharmaceutica on its acquisition from Pfizer of Fosmanogepix, a clinical-stage antifungal candidate with a novel mechanism to treat invasive mold infections.
back to tab navigation
Education
- University of Pennsylvania Law School, JD, 2022
- North Carolina State University, B.S, cum laude, Biological Sciences, 2014
- North Carolina State University, B.A., cum laude, French Language and Literature, 2014
Bar Admission
- State of New York, March 2024
back to tab navigation
